Navigation Links
Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
Date:7/21/2009

ROCKVILLE, Md., July 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of John J. Trizzino as Senior Vice President, International and Government Alliances, a new senior officer position. Mr. Trizzino will report directly to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer, and assume responsibility for developing and managing the company's international alliances with pharmaceutical companies and all governmental agencies, including the US.

Previously, Mr. Trizzino was Vice President of the vaccine franchise at MedImmune, Inc., Senior Vice President of business development at ID Biomedical, and served as Vice President within the Henry Schein, Inc. medical division in business development and General Manager of their GIV division.

Dr. Singhvi stated: "John Trizzino is a talented executive with more than 28 years of broad corporate experience with the last 12 years focused on the vaccine and biotech market. He has managed a number of important flu vaccine products, including FluMist and Fluviral (Flulaval by GSK), created profitable global marketing partnerships, and worked closely with public and private partners including the U.S. Centers for Disease Control and Prevention's national immunization program and the Department of Health and Human Services. In addition, Mr. Trizzino's responsibilities at MedImmune and work with the RSV (Respiratory Syncytial Virus) market should be most valuable to Novavax as we continue development of our own RSV vaccine. I am excited to have him join our Company and look forward to his contributions to our rapidly expanding vaccine business."

Mr. Gary C. Evans, Lead Director of Novavax, commented, "Novavax continues to expand its footprint both here in the US and in the international markets. This is an important new position for our Company and is reflective of the continued evolution of Novavax in the vaccine space. John brings a unique blend of skills in vaccine product positioning strategy, government relations, and commercial markets to augment our existing management team to capitalize on the new opportunities available to the Company."

Mr. Trizzino is a graduate of Long Island University and received his master's degree in business administration from New York University's Stern School of Business.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Repayment of $5 Million of Convertible Debt
2. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
3. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
4. Novavax Appoints Stanley Erck to Board of Directors
5. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
7. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
8. Novavax Reports First Quarter 2009 Financial Results
9. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Early Retirement of $17 Million of Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):